[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$eras](/topic/$eras) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Update: 🎯 $GAP $SES $CORZ $ERAS $CAN $POET all profitable $AMZN AWS is down and I can barely see my screens but these trades are so clean they practically manage themselves 💚" [X Link](https://x.com/Molllz_trade/status/1980308636237992391) [@Molllz_trade](/creator/x/Molllz_trade) 2025-10-20T16:22Z XXX followers, XXX engagements "$IMAB Stock: I-MAB (IMAB $5.77) was a top quarterly gainer rising +181.86%. $ATXS $ABSI $ERAS" [X Link](https://x.com/Tickeron/status/1980248241372598563) [@Tickeron](/creator/x/Tickeron) 2025-10-20T12:22Z 19.4K followers, XXX engagements "Raymond James $RVMD's PT to $XX from $72/keeps at a Strong Buy after RevMed was included in the FDA's NPVR program. $ZLAB AMGN BMY VSTM $IMRX BofAto $XX from $78/reit'd Buy-Top Pick after RevMed was awarded one of the nine NPRVs for daraxonrasib in PDAC. Raymond James said: In a modest surprise to us RevMed's daraxonrasib (RMC-6236) was included in the list which should truncate the time for daraxonrasib to reach the market in 2L RAS-mut pancreatic cancer. Based on the expected accelerated timeline we have adjusted our approval to 4Q26 and slightly increase our price target to $XX. We" [X Link](https://x.com/Quantumup1/status/1979202473425248620) [@Quantumup1](/creator/x/Quantumup1) 2025-10-17T15:06Z 3848 followers, 3778 engagements "$IRD $AEP $AWK $AMBP $BALL $BMNR $CLS $CDTX $CLYM $COGT $CCK $DLR $DUK $EIX $EQIX $ERAS $ES $EXC $FGNX $IT $GTY $NAKA $MDU $NEE $PCG $PNW $PEG $METC $RVTY $RKLB $SBET $SO $SQNS $VERA $VST $VTEX $WEC $XEL $TSLA $ACLX -- THE WSJ" [X Link](https://x.com/notreload_ai/status/1978825300575211951) [@notreload_ai](/creator/x/notreload_ai) 2025-10-16T14:08Z 2960 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Update: 🎯 $GAP $SES $CORZ $ERAS $CAN $POET all profitable $AMZN AWS is down and I can barely see my screens but these trades are so clean they practically manage themselves 💚"
X Link @Molllz_trade 2025-10-20T16:22Z XXX followers, XXX engagements
"$IMAB Stock: I-MAB (IMAB $5.77) was a top quarterly gainer rising +181.86%. $ATXS $ABSI $ERAS"
X Link @Tickeron 2025-10-20T12:22Z 19.4K followers, XXX engagements
"Raymond James $RVMD's PT to $XX from $72/keeps at a Strong Buy after RevMed was included in the FDA's NPVR program. $ZLAB AMGN BMY VSTM $IMRX BofAto $XX from $78/reit'd Buy-Top Pick after RevMed was awarded one of the nine NPRVs for daraxonrasib in PDAC. Raymond James said: In a modest surprise to us RevMed's daraxonrasib (RMC-6236) was included in the list which should truncate the time for daraxonrasib to reach the market in 2L RAS-mut pancreatic cancer. Based on the expected accelerated timeline we have adjusted our approval to 4Q26 and slightly increase our price target to $XX. We"
X Link @Quantumup1 2025-10-17T15:06Z 3848 followers, 3778 engagements
"$IRD $AEP $AWK $AMBP $BALL $BMNR $CLS $CDTX $CLYM $COGT $CCK $DLR $DUK $EIX $EQIX $ERAS $ES $EXC $FGNX $IT $GTY $NAKA $MDU $NEE $PCG $PNW $PEG $METC $RVTY $RKLB $SBET $SO $SQNS $VERA $VST $VTEX $WEC $XEL $TSLA $ACLX -- THE WSJ"
X Link @notreload_ai 2025-10-16T14:08Z 2960 followers, XXX engagements
/topic/$eras/posts